Plus Therapeutics reported Q3 2025 results

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2025, Plus Therapeutics, Inc. (the "Company") reported financial results for the third quarter ended September 30, 2025 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report¹ and incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release Announcing Financial Results, dated October 30, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLUS THERAPEUTICS, INC.

Date:

October 30, 2025

By:

/s/ Marc H. Hedrick, M.D.

Marc H. Hedrick, M.D.

President and Chief Executive Officer

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare²

Presented positive RESPECT-LM Ph1 clinical trial results³

HOUSTON, Texas, October 30, 2025 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025, and provides an overview of recent and upcoming business highlights.

"Our team continues to execute solidly across the three most important business verticals: diagnostics, therapeutics, and capital structure," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "In the fourth quarter, we plan to build on growing momentum in these three areas as we expand our commercial team and footprint for CNSide, seek to clarify our clinical development and pivotal plan for REYOBIQ™ with the FDA⁴, and bolster our financial position in the capital markets."

Q3 2025 AND RECENT HIGHLIGHTS

Corporate

• Received additional $1.9 million advance payment from Cancer Prevention and Research Institute of Texas (CPRIT), the second-largest